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MicroRNA-146a regulates ICOS–ICOSL signalling
to limit accumulation of T follicular helper cells and
germinal centres
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Tight control of T follicular helper (Tfh) cells is required for optimal maturation of the
germinal centre (GC) response. The molecular mechanisms controlling Tfh-cell differentiation
remain incompletely understood. Here we show that microRNA-146a (miR-146a) is highly
expressed in Tfh cells and peak miR-146a expression marks the decline of the Tfh response
after immunization. Loss of miR-146a causes cell-intrinsic accumulation of Tfh and GC B cells.
MiR-146a represses several Tfh-cell-expressed messenger RNAs, and of these, ICOS is the
most strongly cell autonomously upregulated target in miR-146a-deficient T cells. In addition,
miR-146a deficiency leads to increased ICOSL expression on GC B cells and antigen-
presenting cells. Partial blockade of ICOS signalling, either by injections of low dose of ICOSL
blocking antibody or by halving the gene dose of Icos in miR-146a-deficient T cells, prevents
the Tfh and GC B-cell accumulation. Collectively, miR-146a emerges as a
post-transcriptional brake to limit Tfh cells and GC responses.
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T
follicular helper (Tfh) cells provide essential survival and
selection signals to germinal centre (GC) B cells that are
important for long-lived protective antibody responses1,2.
Increasing evidence suggests that restricting Tfh-cell numbers in
GCs is crucial for optimal GC B-cell selection3–5. B cells
expressing the highest affinity receptors after somatic
hypermutation can capture more antigens and therefore have a
competitive advantage in establishing sustained interactions and
eliciting survival signals from Tfh cells5. Studies of autoimmune
mouse models6–9 and human patients10–14 suggest that excessive
Tfh cells may contribute to the pathogenesis of antibody-
mediated autoimmune diseases, potentially by allowing survival
and differentiation of self-reactive B cells. While multiple signals
are now recognized to be important for Tfh-cell formation and
migration3, relatively little is known about the mechanisms that
limit Tfh-cell numbers to achieve optimal selection of high
affinity B-cell clones. Cell-extrinsic mechanisms such as the
actions of T follicular regulatory (Tfr)15–17 and follicular CD8þ
T cells18 have been reported, but to date, only Roquin is shown to
act in a T cell-autonomous manner to prevent spontaneous
accumulation of Tfh cells19.
MicroRNA-146a (miR-146a) has recently emerged as a key
post-transcriptional regulator in hematopoietic cells. MiR-146a
represses TRAF6 and IRAK1 in myeloid cells20 and T cells21 to
control their proliferation and NF-kB activation in response to
Toll-like receptor and TCR signalling, respectively. Deficiency of
miR-146a leads to excessive production of IL-6 and TNF,
myeloproliferation, chronic inflammation and a decline in the
number and quality of hematopoietic stem cells20,22,23. In the
absence of miR-146a, regulatory T (Treg) cells also lose their
suppressive ability due to STAT1 overexpression driving
increased IFN-g secretion24. Not surprisingly, dysregulated
expression of miR-146a has also been found to correlate with
increased incidence of autoimmune diseases, such as lupus25–28
and rheumatoid arthritis29–32.
Here we show that miR-146a profoundly represses Tfh-cell
numbers: the absence of this miRNA leads to spontaneous
Tfh-cell accumulation that precedes myeloid cell dysregulation
and is not a consequence of Treg-cell functional deficiency. This
is achieved by directly repressing multiple messenger RNAs
(mRNAs) targets, most prominently Icos.
Results
MiR-146a is highly expressed in Tfh cells. To identify miRNAs
that might regulate Tfh-cell development and/or function, we
performed a genome-wide expression analysis to identify miR-
NAs that are highly expressed in human Tfh cells. Compared
with naı¨ve (CD44low CD25 ) CD4þ T cells, miR-146a was the
most differentially expressed miRNA (8.2-fold) in Tfh cells
(Fig. 1a) among those that are highly expressed in T cells.
Real-time PCRs on T-cell subsets from human tonsils revealed
that Tfh cells expressed the highest amounts of miR-146a
compared with all other effector (CD44high) subsets (Fig. 1b).
Consistent with these results, a deep-sequencing survey of
the miRNome in mouse tissues showed the highest levels of
miR-146a in Tfh and GC B cells (Fig. 1c and ref. 33). Lower
amounts of miR-146a were also present in activated B cells
and thymic-derived Tregs, while non-haematopoietic tissues
displayed little or no miR-146a expression (Fig. 1c).
MiR-146a expression peaks at the late stage of GC responses.
To study the kinetics of miR-146a expression during a T cell-
dependent immune response, we adoptively transferred 5 105
naı¨ve CD4þ T cells from Ly5bþ OT-II TCR-transgenic mice
into Ly5aþ wild-type C57BL/6 recipient mice, which were then
immunized with ovalbumin (OVA) precipitated in alum and
killed at different time points (Fig. 1d). The proportion of Tfh
cells among donor cells peaked at day 7 post immunization
(Fig. 1e) and started to contract by day 10, coinciding with the
peak of miR-146a expression in transferred cells (Fig. 1e). This
suggests a possible role for miR-146a in downsizing the Tfh-cell
population.
Cell-autonomous control of Tfh cells by miR-146a. To test
whether miR-146a plays a role in the control of Tfh-cell numbers,
we studied Tfh-cell development and function in 12- to 16-week-
old mice lacking miR-146a. Analysis of total follicular T cells,
gated as CXCR5high PD-1high (Fig. 2a,b) or BCL-6high PD-1high
(Fig. 2c,d) cells, showed they were expanded in both percentage
and total number in unimmunized Mir146a / mice compared
with wild-type littermates. This expansion was not selective to
either Tfh (CXCR5high PD-1high Foxp3 ) or Tfr (CXCR5high
PD-1high Foxp3þ ) cells as both subsets increased in parallel
(Fig. 2e). This effect of miR-146a deficiency seemed to affect Tfh
cells more severely than the other effector CD4þ T cell subsets:
compared with the 5-fold increase in Tfh cells, no statistically
significant increases were observed in either Th2 (IL-4þ ) cells or
Th17 (IL-17þ ) cells, while Th1 (IFN-gþ ) cells were increased by
1.4-fold and Tregs (Foxp3þ ), as previously reported24, were
expanded by 1.5-fold (Fig. 2f). Total GC B cells were also
increased by about 20-fold in Mir146a / mice compared with
wild-type littermates (Fig. 2g,h). The spontaneous accumulation
of Tfh and GC B cells became more severe with age
(Supplementary Fig. 1).
To test whether the accumulation of Tfh cells in Mir146a /
mice was due to T-cell intrinsic factors, we set up mixed bone
marrow chimeras by transferring equal amounts of either
Ly5aþ .Mir146aþ /þ : Ly5bþ .Mir146aþ /þ (WT:WT) or Ly5aþ .
Mir146aþ /þ : Ly5bþ .Mir146a / (WT:KO) bone marrow cells
into sub-lethally irradiated Rag1 / recipients. Four months
after reconstitution, the spleens were harvested and the
percentage of total CD4þ T cells, effector cells, Tfh cells, total
B220þ cells and GC B cells derived from the Ly5aþ or Ly5bþ
donor marrow in each mouse was determined (Fig. 3a–d). There
was a higher percentage of total follicular T cells in the WT:KO
chimeras compared with the WT:WT chimeras (Fig. 3a). This
was due to cell-autonomous expansions of Tfh and Tfr cells
derived from Ly5bþ .Mir146a / marrow (Fig. 3b). In each
mouse, there was a two to fourfold increase in Ly5bþ Tfh cells
compared with Ly5aþ Tfh cells, whereas this was not observed in
the control WT:WT chimeras, in which the percentages of Ly5aþ
and Ly5bþ Tfh cells were comparable (Fig. 3b). Importantly, the
percentages of non-follicular effector CD4þ cells were compar-
able between Ly5aþ and Ly5bþ cells in both WT:WT and
WT:KO mixed chimeras. Consistent with previous reports24,
there was a cell-autonomous expansion of non-follicular Tregs
derived from Ly5bþ .Mir146a / marrow in the WT:KO
chimeras (Fig. 3b).
We also observed a statistically significant increase in the
percentage of GC B cells derived from Ly5bþ .Mir146a /
marrow compared with those derived from Ly5aþ .Mir146aþ /þ
bone marrow (Fig. 3c,d), suggesting that miR-146a also acts cell
autonomously in GC B cells. Intriguingly, despite the significant
increase of total follicular T cells in the WT:KO chimeras
(Fig. 3a), we only observed expansion of the Ly5bþ .Mir146a /
GC B cells, while the percentage of the neighbouring Ly5aþ
.Mir146aþ /þ GC B cells was comparable to that in the WT:WT
chimeras (Fig. 3d). This could indicate that GC expansion
requires the concerted actions of miR-146a in T cells and B cells,
perhaps through the regulation of a receptor–ligand pair in each
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cell type. Collectively, these results suggest that miR-146a acts in
T cells and B cells to prevent Tfh and GC B-cell accumulation.
MiR-146a deficiency in T cells initiates Tfh-cell expansion. We
next investigated whether accumulation of Tfh cells could occur
independently of neighbouring Mir146a / B cells and myeloid
cells in the same mice. To this end, we transferred purified naı¨ve
CD4þ T cells from Mir146aþ /þ or Mir146a / OT-II
TCR-transgenic mice into Cd28 / recipients, which were then
immunized with OVA precipitated in alum and killed 7 days
later. There was a statistically significant increase in the percen-
tage of OVA-specific Vb5þ Tfh cells and in the percentage of
total GC B cells in mice that received Mir146a / OT-II cells,
although the magnitude of the effect was smaller than that
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Figure 1 | MiR-146a is highly expressed in Tfh cells. (a) Microarray analysis of miRNA expression in naı¨ve CD4þ Tand Tfh cells. The scatter plot shows
the log2 of averaged (n¼ 3) background-subtracted expression of all Agilent Human miRNA Microarray (V1) Kit 8 15K probes by Tfh cells on the x-axis
compared with naı¨ve CD4þ T cells on the y-axis. Each dot represents one miRNA probe. The dotted lines are drawn at 1.5-fold difference in expression.
(b) Expression of miR-146a, normalized to U6, measured by real-time PCR from human tonsillar T-cell subsets. Cell sorting strategy is described in the
Methods. The heights of the bars represent the mean, and the error bars represent the s.d. of three technical replicates. Data are representative of three
independent experiments. Statistical significance was determined using unpaired Student’s t-test. ***Po0.001, ****Po0.0001. (c) Bar graphs showing the
expression of miR-146a in mouse immune cell subsets and non-hematopoietic tissues as described in Kuchen et al.33. In brief, small RNAs from various
mouse tissues were ligated to adapters using Illumina’s protocol. These were then reverse transcribed, amplified by PCR and sequenced on a Genome
Analyzer (Illumina). (d,e) Kinetics of the Tfh-cell response (filled circles) and miR-146a expression (open circles) from transferred Ly5bþ OT-II cells
analyzed at different time points according to the strategy shown in d. Three recipient mice were killed at each time point. Percentage of Tfh cells among
donor Ly5bþ cells was measured using flow cytometry staining of CD4þ CXCR5high PD-1high Foxp3 T cells. MiR-146a expression was measured by
real-time PCR of total Ly5bþ CD4þ Tcells and was normalized to U6 expression. Filled and open circles in e represent the mean, and error bars represent
the s.d. of biological replicates (for Tfh-cell percentage) or technical replicates (for miR-146a expression).
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Figure 2 | Loss of miR-146a causes spontaneous accumulation of Tfh and GC B cells. (a–d) Flow cytometric contour plots and dot plots showing
percentages and absolute cell number of follicular T cells gated as CXCR5high PD-1high cells (a,b) or BCL-6high PD-1high cells (c,d). (e) Gating strategy for
Tfh (CXCR5high PD-1high Foxp3 ) and Tfr (CXCR5high PD-1high Foxp3þ ) cells and dot plots showing their percentages. (f) Percentages of Th1 (IFN-gþ ),
Th2 (IL-4þ ), Th17 (IL-17þ ), Treg (Foxp3þ ) and Tfh (CXCR5high PD-1high Foxp3 ) cells among total CD4þ cells. (g,h) Flow cytometric contour plots and
dot plots showing percentages and absolute cell numbers of GC B cells. Contour plots shown in a,c,e are gated on CD4þ cells, those in g are gated on
B220þ cells. Unimmunized miR-146a-deficient ( / ) and -sufficient (þ /þ ) mice were analyzed. Each symbol represents one mouse and the
horizontal bars represent the median values. Data are representative of at least three independent experiments. Statistical significance was determined
using Mann–Whitney U-test. NS, not significant, *Po0.05, **Po0.01.
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observed in intact Mir146a / mice (Fig. 3e), suggesting that
non-T cells, including B cells and myeloid cells, enhance this
effect.
In a separate experiment, four different combinations of
Mir146aþ /þ or Mir146a / CD4þ T cells and B cells were co-
transferred into Rag1 / mice, which were immunized 14 days
later with sheep red blood cells (SRBCs; Fig. 3f). Similar to the
OT-II transfer experiment, we found that in the presence of wild-
type B cells and myeloid cells, miR-146a deficiency in T cells was
sufficient to cause Tfh-cell accumulation, although the magnitude
of the effect was again more modest than that observed in intact
Mir146a / mice (Fig. 3g). The presence of Mir146a /
B cells appeared to exacerbate the effect, but this did not reach
statistical significance. Similar trends were observed for the
increase in GC B cells (Fig. 3g). In summary, our data show that
miR-146a deficiency in T cells is sufficient to initiate Tfh and GC
B-cell accumulation, but T-cell-extrinsic factors contribute to
exacerbate this phenotype.
Contribution of IL-6 to Tfh and GC B-cell accumulation. In
view of the reported increased proliferation of myeloid cells in
6- to 8-month-old Mir146a / mice20,34, we asked whether
expanded myeloid compartment could be one of the T-cell-
extrinsic factors contributing to the Tfh and GC B-cell expansion.
Assessments of 12- to 16-week-old mice, when the Tfh-cell
accumulation is obvious (Supplementary Fig. 1), revealed no
significant accumulation of myeloid cell subsets in Mir146a /
mice (Supplementary Fig. 2a).
Myeloid cells and T cells have been reported to produce more
IL-6 cytokine in 6- to 10-month-old miR-146a-null mice20,23.
Since IL-6 is required for Tfh-cell formation35,36, we tested
whether IL-6 production was elevated in 12- to 16-week-old
Mir146a / mice. No significant increase of IL-6 was observed
in the serum of these mice (Supplementary Fig. 2b), and we also
did not find increased amount of Il6 transcripts in CD11chigh
splenic dendritic cells (Supplementary Fig. 2b). Next, we used
Ly5aþ .Mir146aþ /þ : Ly5bþ .Mir146a / mixed bone marrow
chimeras to investigate the possibility that during the course of an
immune response, IL-6 might be expressed at higher levels in
Mir146a / GC B cells, Tfh cells or myeloid cells. Despite the
expected cell-autonomous accumulation of Mir146a / Tfh
cells in the mixed chimeric mice (Supplementary Fig. 3),
no differences in Il6 mRNA expression were found between
miR-146a-sufficient and miR-146a-deficient cells in any of the
subsets examined (Fig. 4a–c). Finally, we tested the possibility
that follicular dendritic cells (FDCs), which are of non-
hematopoietic origin, expressed more IL-6 in the absence of
miR-146a; it has been suggested that FDC-derived IL-6 is
important for the late stage maintenance of Tfh cells during
viral infection35. We isolated FDCs according to published
protocols by gating on CD45 CD31 CD21/35þ cells from
Mir146aþ /þ or Mir146a / mice. As both gp38-expressing37
and non-gp38-expressing38 FDCs have been identified, we
separated these two cell subsets and measured the expression of
IL-6 (Fig. 4d). Again, we did not find evidence of increased Il6
transcripts in either gp38þ or gp38 FDCs from miR-146-
deficient mice (Fig. 4e). Nevertheless, a complete blockade of
IL-6R using a previously reported dose of monoclonal antibody35
greatly reduced Tfh-cell accumulation in Mir146a / mice
(Supplementary Fig. 4), indicating that miR-146a-driven Tfh-cell
accumulation is still dependent on IL-6-mediated signalling.
Intriguingly, we observed enhanced IL-6-induced STAT3
phosphorylation in naı¨ve and effector CD4þ T cells from
Mir146a / mice (Fig. 4f). Lack of increased STAT1 phosphor-
ylation in parallel assays (Supplementary Fig. 5) argued against
STAT1 overexpression being the cause of this enhanced
sensitivity to IL-6. Collectively, these results suggest that
increased IL-6 expression is probably not the main cause of the
Tfh-cell accumulation in miR-146a-deficient mice; rather, the
increased sensitivity to IL-6 signalling is a more likely contributor
to the phenotype.
MiR-146a represses multiple Tfh-cell mRNAs. To uncover
mRNA targets of miR-146a in T cells, we performed a microarray
analysis on sorted naı¨ve CD4þ T cells from Mir146aþ /þ and
Mir146a / mice. A number of differentially expressed genes
were identified and for further validation, we selected putative
targets based on meeting two of the following three criteria:
(1) upregulated mRNA expression in Mir146a / T cells
assessed by global gene expression profiling, (2) known roles in
Tfh and/or GC biology and (3) the presence of target sites for
miR-146a seed region within their 30 untranslated region (UTR).
The selected mRNA targets were Stat1, Cxcr4, Notch1, Slamf1,
Slamf6, Cd84, Icos, Il6st and Il21r (putative miR-146a binding
sites are shown in Supplementary Fig. 6; previously validated
target sites in Cxcr4, Notch1 and Stat1 are not shown).
Next we assessed by flow cytometry whether the proteins
encoded by these putative RNA targets were upregulated in
miR-146a-deficient T cells. STAT1, a validated target of miR-146a
in Tregs24 and an important signalling intermediate and
transcription factor downstream of IL-6, IL-12, IL-21 and
IL-27, was upregulated in Mir146a / naı¨ve CD4þ , Tfh cells
(Fig. 5a) and, as shown previously24, in Tregs (Supplementary
Fig. 7). The validated miR-146a targets CXCR4 (ref. 39), known
to regulate dark zone versus light zone partitioning in GCs5,40,41,
and Notch1 (ref. 42), shown to promote Tfh-cell differentiation43,
were both upregulated in Mir146a / effector CD4þ , Tfh cells
(Fig. 5a) and in Tregs (Supplementary Fig. 7). ICOS is required
for providing costimulatory signals for optimal Tfh and GC B-cell
differentiation44–47 and for persistent directional motility and
follicular recruitment of activated CD4þ T cells48 and failed Icos
mRNA repression is associated with accumulation of Tfh cells in
lupus-prone Roquin-1/2 mutant mice6,19,49. We observed ICOS
overexpression in Mir146a / naı¨ve, effector CD4þ , Tfh cells
(Fig. 5a) and Tregs (Supplementary Fig. 7). Members of the
SLAM family of receptors (SLAMF1, SLAMF6 and CD84)
mediate prolonged interactions between activated antigen-
specific T and B cells and signal via the recruitment of SAP to
promote terminal Tfh-cell differentiation50. SLAMF1, SLAMF6
and CD84 were upregulated in Mir146a / naı¨ve and effector
CD4þ T cells compared with their wild-type counterparts
(Fig. 5a). CD84 was upregulated in Mir146a / Tfh cells
(Fig. 5a), and SLAMF1 and CD84 were also upregulated in
Mir146a / Tregs (Supplementary Fig. 7). IL-21R and IL6ST
are subunits of receptors for the Tfh-cell-inducing cytokines
IL-21 and IL-6, respectively. IL-21R was upregulated in
Mir146a / naı¨ve (Fig. 5a) and Tregs (Supplementary Fig. 7),
while IL6ST was upregulated in Mir146a / naı¨ve and effector
CD4þ T cells (Fig. 5a), but not in Tfh cells (Fig. 5a) or Tregs
(Supplementary Fig. 7).
The putative targets that had not been previously validated
(Slamf1, Slamf6, Cd84, Icos, Il6st and Il21r) were further tested for
direct repression by miR-146a using luciferase reporter assays.
The predicted target sequence from Stat1 revealed a 25%
repression (Supplementary Fig. 8), comparable to that reported
by Rudensky and co-workers24. Similar repression was observed
using luciferase reporters containing the minimal target
sequences from Icos, Slamf1, Slamf6 or Cd84. All of these
targets were specifically repressed by miR-146a, but not by a
‘scramble’ miRNA control (a commercially available, random
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sequence miRNA mimic; Fig. 5b). Luciferase reporter constructs
containing mutations in the sequences recognized by the miR-
146a seed region were no longer repressed by miR-146a. This not
only validated the sequence specificity of the miRNA–mRNA
binding but also mapped the miRNA recognition sequence in the
30UTR (Fig. 5b). By contrast, luciferase reporter constructs
containing the predicted target sequences from Il21r and Il6st
were not repressed by miR-146a (Fig. 5b). Hence, Icos, Slamf1,
Slamf6 and Cd84, but not Il21r and Il6st, are likely to be novel
direct targets of miR-146a.
Luciferase assays reveal targets of miRNAs when the miRNA is
overexpressed in HEK293T cells. To assess which of the above
targets are physiologically relevant and a direct consequence of
miR-146a regulation in CD4þ T cells (naı¨ve, effectors, Treg
and Tfh cells), we assessed their protein expression in Ly5aþ .
Mir146aþ /þ : Ly5bþ .Mir146a / mixed bone marrow
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chimeras. For this, the geometric mean fluorescence intensity was
compared between Ly5aþ and Ly5bþ cells for each target. Of all
targets, the only one that appeared to be controlled cell
autonomously by miR-146a in all CD4þ subsets examined
(including Tfh cells) was ICOS (Fig. 6a). None of the other targets
was cell autonomously upregulated in Tfh cells, but some cell-
autonomous upregulation was observed in naı¨ve CD4þ T cells
(Supplementary Fig. 9: CXCR4, SLAMF1, SLAMF6 and CD84),
effector CD4þ T cells (Supplementary Fig. 9: CXCR4) and Tregs
(Supplementary Fig. 10: CXCR4, SLAMF1, CD84 and STAT1).
As expected from the luciferase assay results, neither IL6ST
nor IL-21R were upregulated in a cell-intrinsic manner in
Mir146a / T cells (Supplementary Figs 9 and 10). Collectively,
our data suggest that miR-146a acts in T cells to directly repress the
expression of Icos, Slamf1, Slamf6, Cd84 and Cxcr4, and of these,
the only cell-autonomous effect in Tfh cells is exerted on Icos.
Increased ICOS signalling in T cells causes Tfh-cell accumulation.
In light of the profound cell-autonomous control of ICOS by
miR-146a and the known roles of ICOS in promoting Tfh-cell
differentiation19,48,51, we set out to formally test the contribution
of excessive ICOS signalling to the expansion of Tfh cells in the
absence of miR-146a. To this end, we first titrated anti-ICOSL
antibody treatment in mice in search of a dose sufficiently low so
as to partially suppress ICOS signalling without abolishing
Tfh-cell formation in wild-type mice. Injections of 25 mg of
anti-ICOSL antibody given every 3 days to wild-type mice after
immunization with SRBCs had no significant effect on wild-type
Tfh cells (Fig. 6b). We then used this anti-ICOSL treatment
regime on 9-week-old Mir146aþ /þ and Mir146a / mice
immunized with SRBC. This treatment completely and
consistently corrected the accumulation of Tfh and GC B cells
in Mir146a / mice and still had no effect on wild-type mice
(Fig. 6c). Of note, the increase in Tregs seen inMir146a / mice
was not consistently corrected by the anti-ICOSL treatment
(Fig. 6c and Supplementary Fig. 11).
We also used a genetic approach to reduce but not eliminate
ICOS expression in Mir146a / mice. Icos hemizygosity was
achieved by crossing Mir146a / to Icos / mice to generate
Mir146a / Icosþ / mice. As seen with the antibody blockade,
lowering Icos gene dose reduced the percentage of Tfh and GC B
cells in Mir146a / Icosþ / mice to the amount seen in
wild-typeMir146aþ /þ Icosþ /þ mice (Fig. 6d). Importantly, Icos
hemizygosity did not rescue Treg-cell accumulation in mice
lacking miR-146a (Fig. 6d), suggesting that dysregulation of Treg
number is not the cause of Tfh-cell accumulation. Thus, our data
indicate that overexpression of ICOS is likely to be a prominent
contributor to the Tfh-cell accumulation in Mir146a / mice.
To exclude the possibility that the observed effect of Icos gene
dose reduction was a consequence of modulating ICOS expres-
sion on Tregs, we co-transferred sorted naı¨ve (CD44low CD25 )
CD4þ T cells from Mir146aþ / or Mir146a / mice, which
were either Icosþ /þ or Icosþ / , with Mir146a / Icosþ /þ
B cells and Mir146aþ /þ Icosþ /þ Tregs into Rag1 / recipient
mice (Fig. 6e). Mir146aþ / mice behaved identically to
Mir146aþ /þ with no evidence of spontaneous Tfh or GC B-cell
accumulation (Supplementary Fig. 12a) or ICOS overexpression
(Supplementary Fig. 12b). Fourteen days after adoptive transfer,
T cells in all experimental groups showed comparable activation
status as measured by the proportion of cells upregulating CD44
or CD25 (Supplementary Fig. 13). Following SRBC immuniza-
tion, recipients of Mir146a / Icosþ / T cells had a B50%
reduction in the percentage of Tfh and GC B cells compared with
those that received Mir146a / Icosþ /þ T cells (Fig. 6f).
Furthermore, halving the gene dose of Icos on Mir146a /
T cells virtually corrected the Tfh-cell accumulation caused by the
lack of miR-146a in T cells: there was no statistically significant
difference between the Mir146aþ / Icosþ /þ and Mir146a /
Icosþ / groups. These results suggest that Icos overexpression in
Tfh-cell precursors is indeed responsible, at least in part, for the
Tfh-cell accumulation in miR-146a-deficient mice.
MiR-146a limits ICOSL in GC B cells and dendritic cells. The
mixed bone marrow chimera results showed that despite the
increase in total follicular T cells in the Ly5aþ .Mir146aþ /þ :
Ly5bþ .Mir146a / chimeras, only the Ly5bþ .Mir146a /
GC B cells, and not the Ly5aþ .Mir146aþ /þ B cells, expanded
(Fig. 3c,d). One of the plausible explanations is that miR-146a co-
ordinately regulates a receptor–ligand pair in Tfh and GC B cells,
so overexpression of both T-cell-expressed receptor and GC
B-cell ligand (or vice versa) are required for Mir146a / GC B
cells to accumulate. Since our data revealed ICOS as the most
prominent target of miR-146a in Tfh cells, and T-cell-expressed
ICOS interacts with B-cell-expressed ICOS ligand (ICOSL) at
different stages of Tfh-cell and GC formation48,51, we assessed
whether miR-146a also regulates ICOSL in B cells. Although we
did not find any predicted miR-146a binding site in Icosl 30UTR,
previous studies have shown that Icosl transcription is regulated
by NF-kB signalling52, which is partly controlled by miR-146a
(refs 20,21,23).
To test whether miR-146a controls ICOSL expression in B
cells, we sorted total B cells from Mir146aþ /þ and Mir146a /
mice, stimulated them in culture for 8 h using lipopolysaccharides
(LPS) or anti-CD40 antibody, and compared ICOSL expression
on either GC or non-GC B cells. No differences in ICOSL
expression were observed in non-GC B cells under any conditions
(Fig. 6g). On the other hand, the expression of ICOSL was
consistently higher in Mir146a / GC B cells—known to be
dependent on NF-kB signalling53–55—across all conditions
(Fig. 6g). An increase in ICOSL expression was also observed in
miR-146a-deficient CD11bþ and CD11cþ cells following
in vitro culture in the absence or presence of LPS (Fig. 6h).
These results suggest that overexpression of ICOSL on GC B cells
and myeloid/dendritic cells are likely to enhance the effects of
increased ICOS expression on Tfh-cell accumulation. They also
suggest that ICOSL overexpression may be required for
Mir146a / GC B-cell expansion when ICOS is concomitantly
overexpressed in T cells.
Finally, we explored the role of other miR-146a targets that
may contribute to the Tfh-cell accumulation. To this end, we
investigated the consequences of genetic manipulation of STAT1
that has known Tfh-cell-promoting effects51 and SLAMF1.
Mir146a / mice were crossed with mice carrying a loss-of-
function mutation in the Stat1 gene (Stat1fae; MGI:3611892) to
generate Mir146a / Stat1fae/þ mice (Supplementary Fig. 14).
The percentages of Tfh and GC B cells in Mir146a / Stat1fae/þ
mice were significantly lower than those in the Mir146a /
Stat1þ /þ mice, but remained about eightfold higher than those
seen in wild-type mice (Supplementary Fig. 14). This result
suggests that STAT1 contributes to the Tfh-cell accumulation in
Mir146a / mice, perhaps by crippling Treg control of Tfh
responses or by actions within Tfh cells and/or other cells. We
also studied the effect of increased Slamf1 copy number in Tfh-
cell formation using NOD.Nkrp1b.Tg(Slamf1)1 (SLAM A—6
copies of Slamf1) and NOD.Nkrp1b.Tg (Slamf1)2 (SLAM B—44
copies56) mice (Supplementary Fig. 15). No differences were
identified in either Tfh-cell or GC formation. Thus, in addition to
the regulation of ICOS, miR-146a also represses ICOSL and
STAT1 expression, which collectively may contribute to the
accumulation of Tfh cells in mice lacking miR-146a.
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Discussion
We have shown that miR-146a, a microRNA highly expressed
in Tfh cells, limits Tfh-cell number. Indeed, in the absence of
miR-146a, there was spontaneous expansion of Tfh and GC B
cells. MiR-146a emerges as the first miRNA to negatively regulate
Tfh-cell accumulation. It therefore opposes the action of the
miR-17B92 cluster, recently shown to promote Tfh-cell
differentiation by repressing Pten, Phlpp2 and Rora mRNAs57,58.
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Our luciferase assays, together with published reports, have
shown that ectopic expression of miR-146a can lead to repression
of multiple Tfh-cell-expressed mRNAs, including Icos, Slamf1,
Slamf6, Cd84, Stat1, Cxcr4 and Notch1. Although all of the above
targets were upregulated in T cells from miR-146a-deficient mice,
ICOS was the only target upregulated cell autonomously in Tfh
cells and the most robustly upregulated across all T-cell subsets
examined. Strikingly, dampening ICOS-mediated signalling in
Mir146a / mice, either by generating Mir146a / Icosþ /
mice or by injecting a suboptimal dose of anti-ICOSL antibody,
completely prevented miR-146a-driven Tfh-cell accumulation.
Furthermore, adoptive transfer experiments in which only non-
Tregs lacked one allele of Icos demonstrated that repressing ICOS
signalling in Tfh-cell precursors themselves, rather than in Tregs,
is required to control Tfh-cell number. This is consistent with
previous reports showing that cell-autonomous Icos mRNA
overexpression due to defective Roquin function contributes to
excessive Tfh-cell number19.
We have also found that miR-146a acts cell autonomously in GC
B cells to limit their number. Increased expression of ICOSL on GC
B cells is a plausible contributor to their accumulation in the
absence of miR-146a, and may explain why despite the striking
increase of Mir146a / Tfh cells in Mir146aþ /þ : Mir146a /
chimeras onlyMir146a / GC B cells expanded. Limiting ICOSL
signalling is likely to be important to prevent excessive B-cell
activation. Indeed, mice overexpressing soluble ICOSL-Fc devel-
oped hypergammaglobulinemia and plasmacytosis59. Our results
suggest that concomitant control of ICOS on Tfh cells and ICOSL
on GC B may be necessary to control the number of GC B cells.
In addition to ICOS–ICOSL regulation, miR-146a-mediated
repression of other T-cell-expressed targets might also contribute
to limit Tfh cells. Our data suggest STAT1 is one such target:
lowering the dose of STAT1 had a significant corrective effect on
Tfh-cell accumulation. This effect is likely to, at least in part, be a
consequence of STAT1 overexpression in Treg cells, including Tfr
cells15, leading to impaired repressive ability24. In addition,
STAT1 is known to function downstream of several Tfh-inducing
cytokines, including IL-6, IL-12, IL-21 and IL-27 (refs 3,51,60),
thus STAT1 overexpression may enhance the sensitivity of miR-
146a-deficient T cells to stimulation by these cytokines and
increase their propensity to differentiate along the Tfh lineage.
Nevertheless, we did not observe an increase in IL-6-induced
STAT1 phosphorylation in Mir146a / T cells. Another
candidate that may contribute to the Tfh-cell accumulation in
miR-146a-deficient mice is IL6ST. We found a subtle increase in
IL6ST expression onMir146a / T cells, although our luciferase
assay data indicate that it is unlikely to be a direct target of
miR-146a. We speculate that increased IL6ST expression in
Mir146a / T cells might cause the observed heightened
sensitivity of these T cells to IL-6 signalling as measured by
STAT3 phosphorylation.
Although this work has focused on identifying Tfh cell-
autonomous targets of miR-146a, the milder phenotype observed
when only T cells lack miR-146a suggests that T-cell extrinsic
factors also contribute to the accumulation of Tfh cells in animals
lacking miR-146a. IL-6, which was increased in aged miR-146a-
deficient mice20,23, did not appear to be upregulated in any
of the cell types examined in 12- to 16-week-old mice, although a
role of IL-6 derived from other haematopoietic cells and/or
non-haematopoietic cells cannot be completely excluded.
Furthermore, given the significant effect of IL-6R blockade
treatment, it is possible that Mir146a / T cells or myeloid cells
do produce increased IL-6 protein in vivo that would not have
been detected by our transcriptional studies. On the other hand,
antigen-presenting cells that are typically CD11cþ and/or
CD11bþ did express increased amounts of ICOSL, which may
enhance T-cell priming and exacerbate Tfh-cell accumulation in
Mir146a / mice61. Tfr cells are required to control Tfh cells
and GC B cells15–17 and have been shown to derive from Foxp3þ
thymic Tregs, which are less functional in Mir146a / mice due
to STAT1 overexpression24. Thus, despite their accumulation, it
is likely that Tfr cells are also defective in Mir146a / mice and
this may also exacerbate the spontaneous Tfh-cell accumulation.
In addition, increased expression of the costimulatory molecules
CD80 (ref. 62) and CD86 (ref. 63) and the reported enhanced
sensitivity of T cells to antigen stimulation21 due to dysregulated
NF-kB activation may also contribute to the Tfh-cell expansion.
It has been reported previously that strong TCR signalling can
skew the differentiation pathway of naı¨ve CD4þ T cells towards
the Tfh lineage64,65. Collectively, all of these miR-146a-mediated
effects in various cell types are likely to act cooperatively to cause
the accumulation of Tfh cells.
In conclusion, this report identifies miR-146a as an important
negative regulator of Tfh and GC B-cell accumulation. It is likely
that this contributes to maintaining immunological tolerance and
preventing the autoimmune phenotypes observed in mice lacking
this microRNA. These findings on miR-146a-mediated control of
Tfh and GC B-cell number may therefore improve our under-
standing of human autoimmunity and inflammatory syndromes.
Note added in proof: A role for miR-146a in repressing miR-
155-induced Tfh-cell accumulation was reported while this work
was under consideration66.
Methods
Mice and immunizations. The mice used were C57BL/6 (B6), B6.Ly5a,
B6.Rag1 / , B6.Cd28 / , B6.OT-II, B6.Mir146a / (ref. 20), B6.Stat1fae/þ ,
Figure 6 | Increased ICOS and ICOSL expression is likely to be the major driver of Tfh-cell accumulation in the miR-146a-deficient mice.
(a) Geometric mean fluorescence intensity (MFI) of ICOS on naı¨ve, effector CD4þ and Tfh cells from Mir146aþ /þ : Mir146a / and Mir146aþ /þ :
Mir146aþ /þ mixed bone marrow chimeras 16 weeks post reconstitution. (b) Percentages of Tfh cells in wild-type mice immunized with sheep red
blood cells (SRBC) and treated with different amounts of anti-ICOSL blocking antibody on days 0, 3 and 6 post immunization. Each symbol represents the
mean and error bars represent the s.d. of three biological replicates. (c) Percentages of Tfh, GC B and Treg cells in 9-week-old wild-type (þ /þ ) and
miR-146a-deficient mice ( / ) treated with 25 mg anti-ICOSL blocking antibody or PBS control on day 0, 3 and 6 following SRBC immunization.
(d) Percentages of Tfh, GC B and Treg cells in 9-week-old Mir146aþ /þ Icosþ /þ , Mir146aþ /þ Icosþ / , Mir146a / Icosþ /þ , Mir146a / Icosþ /
mice following SRBC immunization. (e,f) Adoptive transfer of purified naı¨ve (CD44low CD25 ) CD4þ T cells from either Mir146aþ / Icosþ /þ ,
Mir146aþ / Icosþ / , Mir146a / Icosþ /þ or Mir146a / Icosþ / , together with Mir146a / Icosþ /þ B cells and Mir146aþ /þ Icosþ /þ Tregs
into Rag1 / recipients according to the strategy shown in e. The recipient mice were immunized with SRBC 14 days after transfer and killed 7 days post
immunization. (f) Percentages of Tfh and GC B cells in Rag1 / recipient mice following adoptive transfer and SRBC immunization. (g,h) ICOSL MFI on GC
B (g, left), non-GC B (g, right) and a mixture of CD11bþ and CD11cþ cells (h) from SRBC-immunized wild-type (þ /þ ) or miR-146a-deficient ( / )
mice following stimulation with LPS, anti-CD40 antibody or isotype control. Heights of bars represent the mean and error bars represent s.d. of three
technical replicates. Each symbol represents one mouse and the horizontal bars represent the median values. Data are representative of at least two
independent experiments. Statistical significance was determined using paired Student’s t-test (a), unpaired Student’s t-test (b,g,h) or Mann–Whitney
U-test (c,d,f). NS, not significant, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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B6.Icosþ / (Australian Phenomics Facility, ANU), NOD.Nkrp1b.Tg(Slamf1)1
(ref. 56) and NOD.Nkrp1b.Tg(Slamf1)2 (ref. 56; Immunogenetics Research Facility,
James Cook University). Male and female mice were used in experiments at
approximately equal ratio between the wild-type/untreated and mutant/treated
groups. Mir146a / mice were provided by David Baltimore (Caltech, USA).
Stat1-face (Stat1fae) mice were derived from an N-ethyl N-nitrosourea mutagenesis
screen67 and kindly donated by Christopher C. Goodnow (ANU, Australia).
Mir146a / , Mir146a / Stat1fae/þ , NOD.Nkrp1b.Tg(Slamf1)1 (ref. 56) and
NOD.Nkrp1b.Tg (Slamf1)2 (ref. 56) mice were taken down at 12 to 16 weeks old
unless otherwise stated. All mice were housed under a specific pathogen-free
environment. All experiments were approved by the Australian National University
Animal Experimentation Ethics Committee and the James Cook University Animal
Ethics Committee. To generate thymus-dependent GC responses, where
mentioned, mice were immunized i.v. with 2 108 SRBCs (Applied Biological
Products Management, Australia) and were taken down at day 7 post
immunization.
Human tonsils. Human tonsils were obtained from consenting patients under-
going routine tonsillectomy at the Canberra Hospital (Canberra, Australia) with
the approval from the institutional human research ethics committee. Tonsillar
cells were isolated by mechanical disruption and Ficoll-Paque density gradient
centrifugation.
Adoptive transfers. To study the kinetics of miR-146a expression in a thymus-
dependent GC response, 5 105 sorted naı¨ve OT-II CD4þ T cells were adoptively
transferred into Ly5aþ wild-type B6 recipient mice via i.v. injection. To limit
miR-146a deficiency to T cells, 1 105 sorted naı¨ve Mir146a / OT-II or
Mir146aþ /þ OT-II T cells were adoptively transferred into Cd28 / recipient
mice. The recipients were immediately immunized i.p. with 100 mg OVA (Sigma)
precipitated in alum. To study the contributions of miR-146a deficiency in T and
B cells, 4 106 CD4þ T cells and 6 106 B cells from Mir146aþ /þ or
Mir146a / mice were adoptively transferred into Rag1 / mice. The recipients
were immunized with SRBC 14 days after transfer and they were killed 7 days post
immunization. In addition, to examine the contribution of ICOS overexpression
specifically in Tfh-cell precursors to the Tfh-cell accumulation, 7.5 105 CD44low
CD25 CD4þ T cells from either Mir146aþ / Icosþ /þ , Mir146aþ / Icosþ / ,
Mir146a / Icosþ /þ or Mir146a / Icosþ / donor mice were co-transferred
with 3 106 Mir146a / Icosþ /þ B cells and 7.5 104 Mir146aþ /þ Icosþ /þ
Tregs into Rag1 / recipients. The recipients were bled (to assess the activation
status of T cells) at day 14 following adoptive transfer and immediately immunized
with SRBC. The mice were then killed 7 days post immunization.
Antibodies. Antibodies and streptavidin conjugates used for flow cytometry were
(respective vendors, catalogue numbers and dilutions at which they were used are
shown in parentheses): anti-mouse Ly5a-Pacific Blue (Biolegend, 110722, 1:200),
Ly5a-Alexa Fluor 700 (BD, 561235, 1:200), Ly5b-Alexa Fluor 700 (BD, 560693,
1:200), Ly5b-PerCP Cy5.5 (BD, 552950, 1:200), CD4-Alexa Fluor 700 (BD, 557956,
1:800), CD4-APC Cy7 (BD, 552051, 1:800), B220-PerCP (BD, 553093, 1:800),
CXCR5-biotin (BD, 551960, 1:50), PD-1-PE (BD, 551892, 1:100), PD-1-Brilliant
Violet 421 (BD, 562584, 1:400), CD25-Alexa Fluor 647 (BD, 563598, 1:100),
CD44-APC (BD, 559250, 1:400), CD44-Alexa Fluor 700 (BD, 560567, 1:400),
CD44-PE CF594 (BD, 562464, 1:400), Foxp3-FITC (eBioscience, 11-5773-82,
1:400), Foxp3-eFluor 450 (eBioscience, 48-5773-82, 1:400), GL-7-FITC (BD,
553666, 1:400), Fas-PE Cy7 (BD, 557653, 1:400), Vb5.1/5.2-FITC (BD, 562087,
1:400), ICOSL-PE (Biolegend, 107405, 1:400), CD11b-APC Cy7 (BD, 557657,
1:200), CD11c-PerCP Cy5.5 (BD, 560584, 1:200), IFN-g-FITC (BD, 554411, 1:400),
IL-4-PE Cy7 (BD, 560699, 1:100), IL-17A-Alexa Fluor 700 (BD, 560820, 1:100),
STAT1 (pY701)-Pacific Blue (BD, 560310, 1:5), STAT3 (pY705)-PE (BD, 562072,
1:20), STAT1-Alexa Fluor 647 (BD, 558560, 1:40), CXCR4-biotin (BD, 551968,
1:200), Notch1-PE (BD, 552768, 1:200), ICOS-PE (BD, 552146, 1:200), SLAMF1-
PE (BD, 562651, 1:200), SLAMF6-Alexa Fluor 647 (BD, 561547, 1:100), CD84-PE
(Biolegend, 122806, 1:200), IL-21R-APC (Biolegend, 131910, 1:100), gp130/IL6ST-
APC (R&D Systems, FAB4681A-100, 1:100), CD31-PE (BD, 561073, 1:200),
gp38-Alexa Fluor 488 (eBioscience, 53-5381-82, 1:200), CD21/35-biotin (BD,
562796, 1:200), anti-human CD4-APC Cy7 (BD, 557871, 1:800), CXCR5-Alexa
Fluor 647 (BD, 558113, 1:100), PD-1-PE (eBioscience, 12-9969-42, 1:200),
CD25-PE Cy7 (Biolegend, 356108, 1:100), CD44-Alexa Fluor 700 (BD, 560567,
1:400), and streptavidin-PE Cy7 (BD, 557598, 1:800). Monoclonal blocking anti-
body against ICOSL (clone MIL-5733)68 was provided by A.H. (DRFZ, Germany)
and blocking antibody against IL-6R (catalogue number BE0047, 150 mg per
mouse) was purchased from BioXCell. Mouse anti-CD40 (catalogue number
BE0016-2, 10mgml 1) antibody was also purchased from BioXCell.
Bone marrow chimeras. Chimeras were generated by sub-lethally irradiating
Rag1 / recipient mice (500 cGy, X-rad) and reconstituting their immune system
by transferring 4 106 bone marrow cells from donor mice. Chimeric mice were
taken down 16 weeks post reconstitution unless otherwise stated.
Cell isolation and stimulation. Single-cell suspensions were prepared from
spleens of unimmunized and/or immunized mice. Suspensions were prepared in
RPMI 1640 media (Gibco) supplemented with 10% heat-inactivated foetal calf
serum (FCS), 100U penicillin–streptomycin (Gibco), 2mM L-Glutamine (Gibco),
10mM HEPES (Sigma), 0.1mM non-essential amino acids (Gibco), 1mM sodium
pyruvate (Sigma), 55 mM 2-mercaptoethanol (Gibco) by mechanical disruption and
gentle pipetting through 70 mm nylon mesh filters (BD Biosciences). For cytokine
staining (IFN-g, IL-4 and IL-17), cells were cultured for 4 h in a 37 C/5% CO2
incubator with 50 ngml 1 PMA (Sigma) and 1 mM ionomycin (Sigma) in the
presence of Golgi Stop (BD Biosciences). For ICOSL induction, B220þ cells and
combined CD11bþ /CD11cþ cells were isolated from SRBC-immunized
Mir146aþ /þ orMir146a / mice by negative and positive selection, respectively,
using MACS columns (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. About 5 105 B cells or CD11bþ /CD11cþ cells were cultured per well in a
96-well plate (Corning) with different conditions: complete RPMI only (unsti-
mulated), 1 mgml 1 LPS from Escherichia coli (Sigma), 10 mgml 1 rat IgG2a
isotype control antibody (BioXCell) or 10 mgml 1 rat anti-mouse CD40 antibody
(BioXCell) for 8 h in a 37 C/5% CO2 incubator. To induce IL-6 expression, pur-
ified CD11bþ cells from mixed bone marrow chimeras were stimulated overnight
with 100 ngml 1 LPS (Sigma) in a 37 C/5% CO2 incubator. To study the
responsiveness of T cells to IL-6 signalling, total splenocytes were stimulated with
recombinant mouse IL-6 (20 ngml 1) for 15min in a 37 C/5% CO2 incubator
and levels of STAT3 phosphorylation were analyzed according to published
protocols69.
Flow cytometry. For lymphocyte analysis, single-cell suspensions were prepared as
described in the previous section. For myeloid cell-population analysis, spleens
were treated with Collagenase P (Roche) and DNase I (Sigma) before preparing
single-cell suspensions for staining. FDCs were isolated as described previously35.
Briefly, spleens were digested in 1ml dissociation media (complete RPMI,
1mgml 1 collagenase D, 200 mgml 1 dispase and 100 mgml 1 DNase I) for
30min in a 37 C, 5% CO2 incubator. Cell suspensions were then gently triturated
through P1000 pipette tips and incubated for a further 30min. Dissociated cells
were washed with complete RPMI to remove excess digestive enzymes. To stain for
surface markers, cells were incubated with each antibody layer for 30min in the
dark at 4 C and washed thoroughly with ice-cold FACS buffer (2% FCS and 0.1%
NaN3 in PBS) between each layer. Intracellular staining was performed using the
Intracellular Staining Kit (eBioscience) according to the manufacturer’s
instructions. Serum IL-6 was measured using CBA bead assays (BD Biosciences)
following the manufacturer’s instructions. A BD LSRII Flow Cytometer with
FACSDiva software were used for flow cytometry acquisition and FlowJo (Tree
Star) was used for analysis. FACS Aria (BD Biosciences) was used for cell sorting,
cells were collected in FCS. Tonsillar T cells were sorted using the following
strategy: CD4þ CD25 CD44low CXCR5int/low PD-1int/low naı¨ve T cells, CD4þ
CD25 CD44high CXCR5int/low PD-1int/low non-Tfh effector cells, CD4þ CD25þ
CD44int CXCR5int/low PD-1int/low Tregs, CD4þ CD25 CXCR5high PD-1high Tfh
cells, CD4þ CD25þ CXCR5high PD-1high Tfr cells.
Luciferase reporter assay. HEK293T cells cultured in DMEM media (Gibco)
supplemented with 10% heat-inactivated FCS, 100U penicillin–streptomycin
(Gibco) and 2mM L-Glutamine (Gibco) in 24-well plates were co-transfected with
pmirGLO (Promega) luciferase reporter plasmids containing either wild-type or
mutated putative miR-146a minimal target sequences (Supplementary Table 1;
designed according to pmirGLO’s protocol) and mirVana miR-146a mimic
(Life Technologies) or mirVana negative control #1 (scramble; Life Technologies)
using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s
instructions. The luciferase construct containing Stat1 30UTR was purchased
from Genecopoeia. After 24 h, 3 105 transfected cells were moved into opaque
flat-bottom 96-well plates and incubated for another 24 h. Cells were then
harvested and luciferase activity was assessed using Dual-Glo Luciferase Assay
System (Promega) according to manufacturer’s protocol.
Microarray. Total RNA extraction from sorted tonsillar cells was done using the
RNeasy Kit (QIAGEN) according to the manufacturer’s protocol. RNA quantity
and quality was determined using a Nanodrop 1000 and an Agilent 2100
Bioanalyzer, respectively. Hybridization on Agilent Human miRNA Microarray
(V1) Kit was performed at The Ramaciotti Center for Genomics (University of
New South Wales, Australia). Triplicates (for human miRNA array) were collected
and averaged in GeneSpring. The microarray data has been deposited in NCBI’s
Gene Expression Omnibus and is accessible through GEO Series accession number
GSE64833.
Real-time PCR analysis. RNA was extracted using Trizol reagent (Life
Technologies) according to the manufacturer’s protocol, and complementary DNA
was synthesized using the miScript II reverse transcription Kit (QIAGEN) fol-
lowing the manufacturer’s instructions. Quantitative PCR to detect for miR-146a
expression was performed using the miScript SYBR Green PCR Kit (QIAGEN) and
miScript Primer Assays (QIAGEN) to amplify mature Mir146a and the U6 small
nuclear RNA. Il6 and b-actin mRNAs were amplified using specific primer pairs
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purchased from Origene Technologies(Il6F: 30-TACCACTTCACAAGTCGGA
GGC-50 ; Il6R: 30-CTGCAAGTGCATCATCGTTGTTC-50 ; ActinF: 30-CATTGC
TGACAGGATGCAGAAGG-50 ; ActinR:30-TGCTGGAAGGTGGACAGTG
AGG-50). Quantitative PCR was performed on an Applied Biosystems 7900
machine. The expression ofMir146a was normalized to U6, while the expression of
Il6 was normalized to b-actin. The gene specific expression change was calculated
using the 2DDCt method.
Statistical analysis. Statistical significance was determined using the non-para-
metric Mann–Whitney U-test unless specified otherwise. The sample size was
chosen so that it would be possible to conduct Mann–Whitney test with at least
95% confidence. Consequently in most experiments, at least five mice per group
were used. All statistical analyses were performed using the GraphPad Prism
software. NS, not significant, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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